HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.10 and traded as high as $3.22. HLS Therapeutics shares last traded at $3.1965, with a volume of 3,500 shares traded.
Wall Street Analyst Weigh In
Separately, Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.
Read Our Latest Report on HLTRF
HLS Therapeutics Price Performance
The stock has a 50-day moving average price of $2.78 and a 200 day moving average price of $3.10.
HLS Therapeutics Company Profile
HLS Therapeutics Inc is a specialty pharmaceutical company focused on acquiring, commercializing and supporting prescription medicines. The company primarily targets established or differentiated products that address significant medical needs and have opportunities for expanded access through effective sales, marketing and patient-support programs.
HLS has historically operated mainly in Canada, where it markets pharmaceutical products in areas including central nervous system disorders, cardiovascular health and other specialty-care categories.
Recommended Stories
- Five stocks we like better than HLS Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
